Chromatographic Molecular Weight Measurements for Heparin, Its Fragments and Fractions, and Other Glycosaminoglycans

  • Barbara MulloyEmail author
  • John Hogwood
Part of the Methods in Molecular Biology book series (MIMB, volume 1229)


Glycosaminoglycan samples are usually polydisperse, consisting of molecules with differing length and differing sequence. Methods for measuring the molecular weight of heparin have been developed to assure the quality and consistency of heparin products for medicinal use, and these methods can be applied in other laboratory contexts. In the method described here, high-performance gel permeation chromatography is calibrated using appropriate heparin molecular weight markers or a single broad standard calibrant, and used to characterize the molecular weight distribution of polydisperse samples or the peak molecular weight of monodisperse, or approximately monodisperse, heparin fractions. The same technology can be adapted for use with other glycosaminoglycans.

Key words

Gel permeation chromatography Heparin Heparan sulfate Molecular weight 


  1. 1.
    Al Dieri R, Wagenvoord R, van Dedem GW, Beguin S, Hemker HC (2003) The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif—the C-domain. J Thromb Haemost 1:907–914PubMedCrossRefGoogle Scholar
  2. 2.
    Kailemia MJ, Li L, Xu Y, Liu J, Linhardt RJ, Amster IJ (2013) Structurally informative tandem mass spectrometry of highly sulfated natural and chemoenzymatically synthesized heparin and heparan sulfate glycosaminoglycans. Mol Cell Proteomics 12:979–990PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Volpi N, Maccari F, Suwan J, Linhardt RJ (2012) Electrophoresis for the analysis of heparin purity and quality. Electrophoresis 33:1531–1537PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Sommers CD, Ye H, Kolinski RE, Nasr M, Buhse LF, Al-Hakim A, Keire DA (2011) Characterization of currently marketed heparin products: analysis of molecular weight and heparinase-I digest patterns. Anal Bioanal Chem 401:2445–2454PubMedCrossRefGoogle Scholar
  5. 5.
    Mulloy B, Gee C, Wheeler SF, Wait R, Gray E, Barrowcliffe TW (1997) Molecular weight measurements of low molecular weight heparins by gel permeation chromatography. Thromb Haemost 77:668–674PubMedGoogle Scholar
  6. 6.
    Mulloy B, Heath A, Shriver Z, Jameison F, Al-Hakim A, Morris TS, Szajek A (2014) Development of a compendial method for the chromatographic determination of molecular weight distributions for unfractionated heparin. Anal Bioanal Chem 460:4815–4823Google Scholar
  7. 7.
    Beirne J, Truchan H, Rao L (2011) Development and qualification of a size exclusion chromatography coupled with multiangle light scattering method for molecular weight determination of unfractionated heparin. Anal Bioanal Chem 399:717–725PubMedCrossRefGoogle Scholar
  8. 8.
    Bertini S, Bisio A, Torri G, Bensi D, Terbojevich M (2005) Molecular weight determination of heparin and dermatan sulfate by size exclusion chromatography with a triple detector array. Biomacromolecules 6:168–173PubMedCrossRefGoogle Scholar
  9. 9.
    Mulloy B (2002) Gel permeation chromatography of heparin. In: Volpi N (ed) Analytical techniques to evaluate the structure and function of natural polysaccharides, glycosaminoglycans. Research Signpost, TrivandrumGoogle Scholar
  10. 10.
    Knobloch JE, Shaklee PN (1997) Absolute molecular weight distribution of low-molecular-weight heparins by size-exclusion chromatography with multiangle laser light scattering detection. Anal Biochem 245:231–241PubMedCrossRefGoogle Scholar
  11. 11.
    Huckerby TN, Sanderson PN, Nieduszynski IA (1986) N.M.R. studies of oligosaccharides obtained by degradation of bovine lung heparin with nitrous acid. Carbohydr Res 154:15–27PubMedCrossRefGoogle Scholar
  12. 12.
    Khan S, Gor J, Mulloy B, Perkins SJ (2010) Semi-rigid solution structures of heparin by constrained X-ray scattering modelling: new insight into heparin-protein complexes. J Mol Biol 395:504–521PubMedCrossRefGoogle Scholar
  13. 13.
    Khan S, Fung KW, Rodriguez E, Patel R, Gor J, Mulloy B, Perkins SJ (2013) The solution structure of heparan sulfate differs from that of heparin: implications for function. J Biol Chem 288:27737–27751PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Murphy KJ, Merry CL, Lyon M, Thompson JE, Roberts IS, Gallagher JT (2004) A new model for the domain structure of heparan sulfate based on the novel specificity of K5 lyase. J Biol Chem 279:27239–27245PubMedCrossRefGoogle Scholar
  15. 15.
    Hasan J, Shnyder SD, Clamp AR, McGown AT, Bicknell R, Presta M, Bibby M, Double J, Craig S, Leeming D, Stevenson K, Gallagher JT, Jayson GC (2005) Heparin octasaccharides inhibit angiogenesis in vivo. Clin Cancer Res 11:8172–8179PubMedCrossRefGoogle Scholar
  16. 16.
    Lauder RM, Huckerby TN, Nieduszynski IA, Sadler IH (2011) Characterisation of oligosaccharides from the chondroitin/dermatan sulphates: (1)H and (13)C NMR studies of oligosaccharides generated by nitrous acid depolymerisation. Carbohydr Res 346:2222–2227PubMedCrossRefGoogle Scholar
  17. 17.
    Toida T, Sato K, Sakamoto N, Sakai S, Hosoyama S, Linhardt RJ (2009) Solvolytic depolymerization of chondroitin and dermatan sulfates. Carbohydr Res 344:888–893PubMedCrossRefGoogle Scholar
  18. 18.
    Pomin VH, Park Y, Huang R, Heiss C, Sharp JS, Azadi P, Prestegard JH (2012) Exploiting enzyme specificities in digestions of chondroitin sulfates A and C: production of well-defined hexasaccharides. Glycobiology 22:826–838PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Volpi N, Bolognani L (1993) Glycosaminoglycans and proteins: different behaviours in high-performance size-exclusion chromatography. J Chromatogr 630:390–396PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.National Institute for Biological Standards and ControlHertfordshireUK
  2. 2.Institute of Pharmaceutical ScienceKing’s College LondonLondonUK

Personalised recommendations